TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Tanios S Bekaii-Saab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.